Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: erythropoietin gene therapy - ARIAD

Drug Profile

Research programme: erythropoietin gene therapy - ARIAD

Alternative Names: AAV-mediated erythropoietin gene therapy - Ariad; Adeno-associated viral vector-mediated erythropoietin gene therapy - Ariad

Latest Information Update: 17 Feb 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Class Antianaemics; Gene therapies; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Retinitis pigmentosa

Most Recent Events

  • 16 Feb 2017 ARIAD Pharmaceuticals has been acquired by Takeda
  • 08 Nov 2006 Discontinued - Preclinical for Retinal disorders in Italy (unspecified route)
  • 08 Nov 2006 Discontinued - Preclinical for Retinal disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top